Skip to main content
. 2017 Apr 14;8(42):73144–73153. doi: 10.18632/oncotarget.17113

Table 1. Patients’ characteristics by dose levels.

Characteristics Dasatinib Dose Level (mg)
Dose Level 1
100 (n = 6)
Dose Level 2
140 (n= 4)
All patients
(n= 10)
Age, years (median; range) 44 (35-81) 49 (47-73) 48 (35- 81)
Race, n (%)
Caucasian 5 (83) 4 (100) 9 (90)
Hispanic 1 (17) 0 (0) 1 (10)
ECOG PS, n (%)
0 2 (33) 3 (75) 5 (50)
1 4 (67) 1 (25) 5 (50)
Menopausal status, n (%)
Premenopausal 4 (67) 1 (25) 5 (50)
Postmenopausal 2 (33) 3 (75) 5 (50)
Hormone receptors, n (%)
ER+ / PgR+ 4 (67) 1 (25) 5 (50)
ER+ / PgR- 1 (17) 1 (25) 2 (20)
ER- / PgR- 1 (16) 2 (50) 3 (30)
Previous trastuzumab treatment
Yes 2 (33) 2 (50) 4 (40)
No 4 (67) 2 (50) 6 (60)
Previous hormonotherapy treatment
Yes 4 (67) 1 (25) 5 (50)
No 2 (33) 3 (75) 5 (50)
Previous radiotherapy treatment
Yes 1 (17) 2 (50) 3 (30)
No 5 (83) 2(50) 7 (70)
Other previous chemotherapy or biological treatment
Yes 2 (33) 2 (50) 4 (40)
No 4 (67) 2 (50) 6 (60)

mg: milligram; n: number of patients; ECOG: Eastern Cooperative Oncology Group; PS: performance status; ER: estrogen receptor; PgR: progesterone receptor.